Bank of America Upgrades DENTSPLY SIRONA (NASDAQ:XRAY) to “Buy”

DENTSPLY SIRONA (NASDAQ:XRAY) was upgraded by analysts at Bank of America from a “neutral” rating to a “buy” rating in a note issued to investors on Thursday, MarketBeat reports. The firm currently has a $17.00 price objective on the medical instruments supplier’s stock, up from their previous price objective of $13.00. Bank of America‘s target price suggests a potential upside of 35.57% from the company’s previous close.

XRAY has been the topic of a number of other reports. Wells Fargo & Company reduced their target price on shares of DENTSPLY SIRONA from $15.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Friday, November 7th. Barrington Research reissued an “outperform” rating and issued a $14.00 price objective on shares of DENTSPLY SIRONA in a research report on Monday, January 5th. UBS Group lowered their target price on DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. JPMorgan Chase & Co. cut their price target on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Finally, Mizuho raised their price objective on DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Tuesday, January 20th. Three research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $14.46.

DENTSPLY SIRONA Trading Up 0.2%

NASDAQ:XRAY opened at $12.54 on Thursday. The business’s 50-day moving average is $12.23 and its two-hundred day moving average is $12.49. The firm has a market capitalization of $2.50 billion, a PE ratio of -2.84, a price-to-earnings-growth ratio of 0.98 and a beta of 1.01. DENTSPLY SIRONA has a 12 month low of $9.85 and a 12 month high of $19.27. The company has a debt-to-equity ratio of 1.36, a current ratio of 1.47 and a quick ratio of 0.99.

Insiders Place Their Bets

In other news, Director Gregory T. Lucier sold 82,200 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $11.14, for a total transaction of $915,708.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.50% of the stock is currently owned by corporate insiders.

Institutional Trading of DENTSPLY SIRONA

Hedge funds have recently modified their holdings of the business. Eurizon Capital SGR S.p.A. acquired a new stake in shares of DENTSPLY SIRONA during the 4th quarter worth approximately $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of DENTSPLY SIRONA during the first quarter valued at approximately $26,000. Parkside Financial Bank & Trust increased its stake in shares of DENTSPLY SIRONA by 620.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 1,477 shares during the period. Huntington National Bank raised its position in shares of DENTSPLY SIRONA by 292.9% during the third quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,077 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of DENTSPLY SIRONA by 337.9% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 2,122 shares during the period. Hedge funds and other institutional investors own 95.70% of the company’s stock.

Key Headlines Impacting DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Bank of America upgraded XRAY from Neutral to Buy and raised its price target to $17 from $13 (about 35.6% upside vs. the current price). The upgrade is being cited as the primary catalyst for intraday gains. B of A Securities Upgrades DENTSPLY SIRONA (XRAY) Dentsply Sirona gains as BofA upgrades to Buy on risk-reward setup
• Neutral Sentiment: The company is expected to announce quarterly earnings on Thursday, which increases near-term volatility and focus on results vs. guidance. Investors should watch the report for revenue trends and margin commentary. DENTSPLY SIRONA (XRAY) Expected to Announce Earnings on Thursday
• Neutral Sentiment: Short-interest data reported in the last two days shows anomalous figures (zeros/NaN), suggesting a reporting error rather than a true surge in shorting; this makes short-interest-driven moves unlikely unless corrected data emerges.
• Negative Sentiment: A Zacks preview warns that XRAY lacks the setup for an earnings beat in the coming report, which could cap upside and lead to a pullback if results or guidance disappoint. Traders should weigh the upgrade optimism against this caution. Dentsply International (XRAY) Earnings Expected to Grow: What to Know Ahead of Next Week’s Release

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.